ZilvER ptx with cilOstazol in Superficial femoral artery

ZilvER ptx with cilOstazol in Superficial femoral artery - ZERO trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032473

Enrollment

Registered

2018-06-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PAD

Interventions

For SFA lesions Stenting DES(Zilver PTX) 1 year oral administration of Cilostazol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: TBA

Exclusion criteria

Exclusion criteria: TBA

Design outcomes

Primary

Measure	Time frame
TBA	—

Countries

Japan

Contacts

Public ContactTakashi Miura

Nagano Municipal Hospital Cardiology

miuramen10miuramen@yahoo.co.jp0262951199

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026